<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281736</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000441205</org_study_id>
    <secondary_id>I 30404</secondary_id>
    <nct_id>NCT00281736</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer</brief_title>
  <official_title>A Phase II Study of HPPH Photodynamic Therapy for Treatment of High Grade Dysplasia, Carcinoma In-Situ or Early Intramucosal Adenocarcinoma in Barrett's Esophagus. Randomization to Two PDT Treatment Regimens of HPPH (2-1 [Hexyloxyethyl]-2devinylpyropheophorbide-a) and Light</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that is absorbed by tumor cells.&#xD;
      The drug becomes active when it is exposed to light, and kills tumor cells. HPPH may be&#xD;
      effective in killing precancerous cells and tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well photodynamic therapy with HPPH&#xD;
      works in treating patients with precancerous esophageal conditions or stage 0 or stage I&#xD;
      esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine response in patients with high-grade dysplasia, carcinoma in situ, or early&#xD;
           intramucosal adenocarcinoma of the esophagus and Barrett's esophagus treated with&#xD;
           photodynamic therapy using HPPH.&#xD;
&#xD;
        -  Determine the safety, in terms of toxicity to surrounding normal tissue, of this regimen&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen on surrounding normal tissue in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the incidence of adenocarcinoma in these patients after this treatment.&#xD;
&#xD;
        -  Determine the magnitude and duration of increased skin sun sensitivity in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the minimal erythemal dose of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to presence of&#xD;
      intramucosal tumor (yes vs no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the&#xD;
           lesion is exposed to laser light endoscopically.&#xD;
&#xD;
        -  Arm II: Patients receive HPPH as in arm I, but at a higher dose, followed by laser light&#xD;
           exposure.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this&#xD;
      study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the lesion is exposed to laser light endoscopically.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive HPPH as in arm I, but at a higher dose, followed by laser light exposure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPPH</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed high-grade dysplasia, carcinoma in situ, or early&#xD;
             intramucosal adenocarcinoma of the esophagus&#xD;
&#xD;
               -  Stage 0 or N0, M0 primary or recurrent disease&#xD;
&#xD;
          -  Diagnosis of Barrett's esophagus&#xD;
&#xD;
          -  Ineligible for or refused surgical resection&#xD;
&#xD;
          -  Requires endoscopy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 4,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  PT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
          -  ALT ≤ 3 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No contraindication to endoscopy&#xD;
&#xD;
          -  No other malignancy except nonmelanoma skin cancer or another cancer for which patient&#xD;
             is deemed disease-free&#xD;
&#xD;
          -  No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 1 month since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 1 month since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 1 month since prior Nd-YAG laser therapy&#xD;
&#xD;
          -  At least 4 weeks since prior therapy for this disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hector R. Nava, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage 0 esophageal cancer</keyword>
  <keyword>stage I esophageal cancer</keyword>
  <keyword>precancerous condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

